Related Experiment Video
Updated: Aug 7, 2026
09:56
Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
Published on: August 2, 2016
Pharmaceutical aspects of docetaxel
1Investigational Drug Section, Institute for Drug Development, San Antonio, TX 78229, USA.
Summary
This review covers docetaxel clinical trials and pharmacokinetics. Docetaxel is effective for advanced breast cancer, with a recommended dose of 100 mg/m2 and a 47% response rate in anthracycline-resistant cases.
Area of Science:
- Oncology
- Pharmacology
- Clinical Pharmacy
Background:
- Docetaxel is a chemotherapy agent used for various cancers.
- Understanding its clinical trial data, pharmacokinetics, and pharmaceutical preparation is crucial for effective use.
Purpose of the Study:
- To review the clinical trials, pharmacokinetics, and pharmaceutical aspects of docetaxel.
- To provide guidance on dosage, administration, and preparation for healthcare professionals.
Main Methods:
- Review of Phase I and Phase II clinical trial data.
- Analysis of pharmacokinetic studies.
- Evaluation of pharmaceutical formulations and preparation guidelines.
Main Results:
- Maximum tolerated dose in Phase I trials: 80-115 mg/m2; dose-limiting toxicity: neutropenia.
- Recommended Phase II dose: 100 mg/m2 every three weeks.
- Docetaxel exhibits linear pharmacokinetics with a ~12-hour half-life.
- Overall response rate of 47% in anthracycline-resistant breast cancer.
- Hepatic dysfunction increases drug concentration and adverse effects.
- Commercial formulations require specific preparation to achieve a 10 mg/mL concentration.
Conclusions:
- Docetaxel is indicated for advanced or metastatic breast cancer resistant to anthracyclines.
- Careful attention to preparation and administration is necessary to avoid dosage errors.
- Docetaxel is suitable for outpatient administration.
Related Concept Videos
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
01:10Drugs that Destabilize Microtubules
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
01:21Drug Distribution: Tissue Binding
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
For...
01:24Tissue-Drug Binding: Localization of Drugs and its Significance
Body tissues, comprising approximately 40% of the body weight, are crucial in drug distribution and localization. These tissues can serve as drug storage sites, competing with plasma binding sites for drug molecules.
Drugs can bind to different tissue components, enhancing their distribution and localization. The factors influencing drug localization in tissues include the drug's lipophilicity, structural characteristics, tissue perfusion rate, and pH differences. These factors determine the...
Drugs can bind to different tissue components, enhancing their distribution and localization. The factors influencing drug localization in tissues include the drug's lipophilicity, structural characteristics, tissue perfusion rate, and pH differences. These factors determine the...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...